Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,964
Views
0
CrossRef citations to date
0
Altmetric
Author's View

Tissue-resident memory T cells in immune-related adverse events: friend or foe?

Robin Reschkea Department of Pathology, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA;b Department of Dermatology and Venerology and Fleur Hiege-Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, GermanyView further author information
&
Thomas F Gajewskia Department of Pathology, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA;c Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USACorrespondence[email protected]
View further author information
Article: 2197358 | Received 18 Mar 2023, Accepted 27 Mar 2023, Published online: 04 Apr 2023

References

  • Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022 Apr;19(4):254–3. doi:10.1038/s41571-022-00600-w.
  • Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021 Aug;20(8):883–888. doi:10.1080/14740338.2021.1915279.
  • Schreiner D, King CG. CD4+ memory T cells at home in the tissue: mechanisms for health and disease. Front Immunol. 2018 Oct 16;9:2394. doi:10.3389/fimmu.2018.02394.
  • Hu ZI, Link VM, Lima-Junior DS, Delaleu J, Bouladoux N, Han S-J, Collins N, Belkaid Y. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proc Natl Acad Sci. 2022 Jun 28;119(26):e2200348119. doi:10.1073/pnas.2200348119.
  • Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF. Checkpoint blockade–Induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 Oct 4;10(10):1167–1174. doi:10.1158/2326-6066.CIR-22-0362.
  • Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 Apr 12;13(1):1970. doi:10.1038/s41467-022-29539-3.
  • Kalinoski HM, Won T, Rusinkevich V, Talor MV, Hughes DM, Wood MK, Hooper JE, Cihakova D. Myosin specific TRM cells mediate increased severity of immune checkpoint inhibitor myocarditis. J Immunol. 2021 MayApr 122 cited 2022];206(1_Supplement).98.52. https://www.jimmunol.org/content/206/1_Supplement/98.52.
  • Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, Ferreira RC, Trzupek D, Gupta T, Al-Hillawi L, et al. Interferon-Gamma–Producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor–Colitis. Gastroenterology. 2021 Oct;161(4):1229–1244.e9. doi:10.1053/j.gastro.2021.06.025.
  • Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020 Aug 6;182(3):655–671.e22. doi:10.1016/j.cell.2020.06.001.
  • Basin S, Perrin J, Michot J-M, Lambotte O, Cauquil C. Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy. Eur J Cancer. 2021 Mar;145:230–233. doi:10.1016/j.ejca.2020.12.014.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.